ELIQUIS (apixaban) 5mg tablets by Bristol-Myers Squibb and Pfizer Bristol-Myers Squibb and Pfizer announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application ...

ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One ...

Whether or not Eliquis 5mg* twice daily is non-inferior or superior to VKAs for the outcome of major or CRNM bleeding, as defined by the International Society on Thrombosis and Haemostasis (ISTH), in ...

(HealthDay News) — For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...

Bristol-Myers Squibb and Pfizer announced results from the pre-specified secondary analysis of the Phase 3 AMPLIFY-EXT (Apixaban after the initial Management of PuLmonary embolIsm and deep vein ...

Choice of direct oral anticoagulant (DOAC) mattered for clinical outcomes among adults with atrial fibrillation (Afib), a study based on U.S. insurance claims found. Apixaban (Eliquis) users had ...

Patients with A-fib and only one of the three dose-reduction criteria used in the ARISTOTLE trial—age 80 years or older, body weight 60 kg or less, and creatinine level 1.5 mg/dL or higher—have higher ...

The novel oral anticoagulant apixaban has similar effects on stroke, systemic embolism and major bleeding in patients with atrial fibrillation (A-fib) whether they have been on previous warfarin ...

The study, known as the Apixaban versus Acetylsalicylic Acid to Prevent Strokes in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, ...

In the ARISTOTLE trial of apixaban versus warfarin for stroke prevention in patients with atrial fibrillation, those with two or more dose-reduction criteria (aged ≥80 years, weight ≤60 kg, creatinine ...

Please provide your email address to receive an email when new articles are posted on . Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous ...

Bristol-Myers Squibb Company has announced that the company is voluntarily recalling one lot of Eliquis 5 mg tablets to the consumer level. This lot was distributed nationwide in the US to wholesalers ...